CD47 Targeting Therapeutics Market is expected to grow at a 35% CAGR during the forecast period for 2028-2034.
Key Industry Insights & Findings from the Report:
CD47 is immunoglobulin and supramolecular complex composed of integrins, G protein, and cholesterol. It mediates a series of processes such as cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, and inhibition of NO signalling. In recent years, CD47 also called the “don’t eat me” signal, has been highly expressed on the surface of various cancers, initiating an inhibitory signalling pathway that prevents cancer cells from phagocytosis by macrophages.
The factors driving the growth of the CD47 targeting therapeutics market include the rising developments in the CD47-targeting anti-cancer therapies, growing demand for cost-efficient cancer treatments, increasing government initiatives for cancer awareness, and R&D initiatives by market players for launching effective cancer therapies, and the growing number of cancer cases worldwide. According to the NCI (National Cancer Institute), cancer is among the leading causes of death worldwide. By 2040, more cancer cases are expected to rise to 29.5 million per year and cancer-related deaths to 16.4 million. Recently, the American FDA has granted orphan drug designation ("ODD") to ALX Oncology's next-generation CD47 blocker ‘evorpacept’ for treating patients with gastroesophageal junction cancer and gastric cancer. Thus, the increasing prevalence of cancer is projected to surge the demand for advanced cancer therapies to treat cancer patients effectively, which will likely fuel the market growth over the forecast period. However, the high R&D cost of target therapies and side effects associated with these therapies are expected to hamper the market’s growth in the coming years.
The CD47 targeting therapeutics market is classified based on target disease indication, type of molecule, and region. The target disease indication, segment the market into acute myeloid leukemia, non-hodgkin lymphoma, colorectal cancer, diffuse large B-cell lymphoma, myelodysplastic syndromes, non-small cell lung cancers, ovarian epithelial cancer, oral mucositis, small cell lung cancers, and other disease indications. The acute myeloid leukaemia segment is anticipated to proliferate over the forecast period owing to the increased CD47 expression on human AML. The market is grouped into biologics and small molecules by type of molecule. Due to its increasing therapeutic applications, the biologics segment is expected to witness significant growth during the forecast years. Regionally, the market is considered across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa.
North America is likely to witness the highest growth during the forecast period due to the high prevalence of cancer, growing demand for CD47 therapeutic products, and the increasing approvals for immunoglobulins.
|
Report Attribute |
Specifications |
|
Growth rate CAGR |
CAGR of 35% from 2028 to 2034 |
|
Quantitative units |
Representation of revenue in US$ Million and CAGR from 2028 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2028-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments covered |
By Target disease Indication, By Type of Molecule |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Conjupro biotherapeutics (US), EpicentRx (US), Forty Seven (US), ImmuneOncia Therapeutics (Korea), ImmuneOnco Biopharmaceuticals (China), Innovent Biologics (China), KAHR Medical (Israel), Light Chain Bioscience (Switzerland), Morphiex (US), Trillium Therapeutics (Canada), TG Therapeutics, Adagene, Alector, Inc., Apmonia Therapeutics, I-MAB Biopharma Co., Ltd., QLSF Biotherapeutics Inc., Phanes Therapeutics, Inc., Bio-Thera Solutions, others. |
|
Customization scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and available payment methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global CD47 Targeting Therapeutics Market Snapshot
Chapter 4. Global CD47 Targeting Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 2: By Target Disease Indication Estimates & Trend Analysis
5.1. By Target Disease Indication & Market Share, 2028 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Target Disease Indication:
5.2.1. Acute Myeloid Leukemia
5.2.2. Non-Hodgkin Lymphoma
5.2.3. Colorectal Cancer
5.2.4. Diffuse Large B-cell Lymphoma
5.2.5. Myelodysplastic Syndromes
5.2.6. Non-Small Cell Lung Cancers
5.2.7. Ovarian Epithelial Cancer
5.2.8. Oral Muscositis
5.2.9. Small Cell Lung Cancers
Chapter 6. Market Segmentation 4: By Molecules Estimates & Trend Analysis
6.1. By Molecules & Market Share, 2028 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Molecules:
6.2.1. Biologics
6.2.2. Small Molecule
Chapter 7. CD47 Targeting Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Target Disease Indication, 2021-2034
7.1.2. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts By Types, 2021-2034
7.1.3. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.1.4. North America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.2.2. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.2.3. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.2.4. Europe CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.3.2. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.3.3. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.3.4. Asia Pacific CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.4.2. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.4.3. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.4.4. Latin America CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Target Disease Indication, 2021-2034
7.5.2. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) By Types, 2021-2034
7.5.3. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) estimates and forecasts by Molecules, 2021-2034
7.5.4. Middle East & Africa CD47 Targeting Therapeutics Market revenue (US$ Million) by country, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Abpro
8.2.2. ALX Oncology
8.2.3. Apmonia Therapeutics
8.2.4. Arch Oncology
8.2.5. Aurigene
8.2.6. Bristol Myers Squibb
8.2.7. Conjupro biotherapeutics
8.2.8. EpicentRx
8.2.9. Forty Seven
8.2.10. ImmuneOncia Therapeutics
8.2.11. ImmuneOnco Biopharmaceuticals
8.2.12. Innovent Biologics
8.2.13. KAHR Medical
8.2.14. Light Chain Bioscience
8.2.15. Morphiex
8.2.16. Trillium Therapeutics
8.2.17. TG Therapeutics
8.2.18. Adagene
8.2.19. Alector, Inc.
8.2.20. Apmonia Therapeutics
8.2.21. I-MAB Biopharma Co., Ltd.
8.2.22. QLSF Biotherapeutics Inc.
8.2.23. Phanes Therapeutics, Inc.
8.2.24. Bio-Thera Solutions
8.2.25. Other Prominent Players
Global CD47 Targeting Therapeutics Market, by Target Disease Indication, 2022-2030 (Value US$ Mn)
Global CD47 Targeting Therapeutics Market, by Type of Molecule, 2022-2030 (Value US$ Mn)
Global CD47 Targeting Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)
North America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Europe CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Asia Pacific CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Latin America CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Middle East & Africa CD47 Targeting Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)
Competitive Landscape
Other Prominent Players
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
